 |
市場調查報告書
商品編碼
1532550
卡介苗疫苗市場 - 按年齡層（兒科、成人）、按應用（結核、膀胱癌）、最終用途（醫院、診所）和預測，2024 - 2032 年BCG Vaccines Market - By Age Group (Pediatrics, Adults), By Application (Tuberculosis, Bladder Cancer), By End-use (Hospitals, Clinics) & Forecast, 2024 - 2032 |
||||||
由於全球結核病的高流行，2024 年至 2032 年間，全球卡介苗疫苗市場的複合年成長率將達到 5.4%。全球結核病的持續負擔，特別是在發展中國家，刺激了對卡介苗疫苗的需求。
根據世界衛生組織估計，2022 年全球估計有1,060 萬人感染結核病，高於2021 年的1,030 萬人和2020 年的1,000 萬人，標誌著到2020 年之前持續下降的趨勢持續扭轉。率（新病例）據估計，2020-2021 年和 2021-2022 年期間，每 10 萬人的死亡率增加了 1.9%。隨著越來越多的人罹患結核病，特別是在高風險地區，各國政府和衛生組織加強了免疫接種。這種對透過疫苗接種預防結核病的高度重視極大地促進了卡介苗疫苗市場的成長。
整個卡介苗疫苗產業根據年齡層、應用、最終用途和地區進行分類。
成人市場將在 2024 年至 2032 年期間獲得可觀的收益。成年人對卡介苗的需求受到多種因素的推動，包括結核病病例的增加以及高危險群（例如醫護人員和免疫系統較弱的人群）的保護需求。此外，卡介苗疫苗在膀胱癌治療中的潛在治療用途也增加了成人對其的需求。人們對結核病預防和疫苗接種益處的認知的提高進一步鼓勵了成人免疫接種。此外，全球旅行和移民使更多成年人接觸結核病流行地區，促使接種疫苗作為預防措施。衛生組織的公共衛生措施和建議在推動成人卡介苗疫苗接種方面也發揮重要作用。
由於卡介苗疫苗在治療非肌肉浸潤性膀胱癌 (NMIBC) 方面已被證實的功效，膀胱癌細分市場可能會在 2024 年至 2032 年期間刺激卡介苗疫苗市場的應用前景。卡介苗療法透過刺激免疫系統攻擊癌細胞，顯著降低癌症復發和進展的風險。臨床研究和長期患者結果支持其有效性，使其成為標準治療選擇。此外，膀胱癌發生率的增加以及對具有成本效益的非手術治療方案的需求也推動了需求。正在進行的研究和積極的臨床試驗結果進一步驗證了 BCG 對膀胱癌的治療效果，鼓勵在醫療實踐中廣泛採用。
由於弱勢群體結核病發病率上升以及結核病預防意識增強，到 2032 年，北美卡介苗市場的估值將保持適度。政府對免疫計劃的大力支持和資助確保了疫苗的廣泛供應和分發。此外，人們對卡介苗疫苗在治療非肌肉浸潤性膀胱癌中的作用的日益認知也推動了其在腫瘤學領域的應用。先進的醫療基礎設施、強勁的研發活動以及嚴格的監管標準進一步支持市場成長。公共衛生活動和疾病預防控制中心等衛生組織的建議強調了卡介苗疫苗接種的重要性，有助於市場擴張。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 結核病 (TB) 發生率不斷上升
- 研發投資激增
- 提高疫苗接種計劃的認知和採用
- 產業陷阱與挑戰
- 疫苗短缺和供應鏈挑戰
- 成長動力
- 成長潛力分析
- 報銷場景
- 監管環境
- 技術景觀
- 擴大卡介苗疫苗的應用
- 定價分析
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司市佔率分析
- 公司矩陣分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 戰略儀表板
第 5 章：市場估計與預測：按年齡分類，2021 - 2032
- 主要趨勢
- 兒科
- 成年人
第 6 章：市場估計與預測：按應用分類，2021 - 2032
- 主要趨勢
- 結核
- 膀胱癌
第 7 章：市場估計與預測：按最終用途，2021 - 2032 年
- 主要趨勢
- 醫院
- 診所
第 8 章：市場估計與預測：按地區分類，2021 - 2032 年
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
- 亞太地區
- 印度
- 中國
- 印尼
- 菲律賓
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
第 9 章：公司簡介
- AJ Biologics Sdn Bhd
- BCG Vaccine Laboratory
- Biomed Lublin S.A.
- GSBPL
- Japan BCG Laboratory
- Merck & Co., Inc.
- Microgen
- Serum Institute of India Pvt. Ltd.
- Taj Pharmaceuticals Limited
- Zydus Group
Global BCG Vaccines Market will demonstrate 5.4% CAGR between 2024 and 2032, attributed to the high prevalence of Tuberculosis worldwide. The ongoing global burden of Tuberculosis, particularly in developing countries, fuels the demand for BCG vaccines.
According to WHO, an estimated 10.6 million people contracted TB globally in 2022, up from 10.3 million in 2021 and 10.0 million in 2020, marking a continued reversal of the previously sustained downward trend up to 2020. Similarly, the Tuberculosis incidence rate (new cases per 100,000 population per year) is assessed to have risen by 1.9% between 2020-2021 and 2021-2022. As more people fall ill with TB, especially in high-risk regions, governments and health organizations intensify immunization efforts. This heightened focus on TB prevention through vaccination significantly contributes to the growth of the BCG vaccines market.
The overall BCG vaccines industry is segregated based on age group, application, end-use, and region.
The adults segment will garner appreciable gains throughout 2024-2032. The demand for BCG vaccines among adults is favored by several factors, including the rise in TB cases and the need for protection in high-risk populations, such as healthcare workers and those with weakened immune systems. In addition, the BCG vaccine's potential therapeutic use in bladder cancer treatment has increased its demand among adults. Heightened awareness about TB prevention and the benefits of vaccination further encourage adult immunization. Moreover, global travel and migration expose more adults to TB-endemic regions, prompting vaccination as a preventive measure. Public health initiatives and recommendations by health organizations also play a significant role in driving adult BCG vaccination.
The bladder cancer segment could stimulate the application landscape of the BCG vaccines market over 2024-2032, propelled by the proven efficacy of BCG vaccines in treating non-muscle invasive bladder cancer (NMIBC). BCG therapy significantly reduces the risk of cancer recurrence and progression by stimulating the immune system to attack cancer cells. Clinical studies and long-term patient outcomes support its effectiveness, making it a standard treatment option. Additionally, increasing bladder cancer incidence rates and the need for cost-effective, non-surgical treatment options drive demand. Ongoing research and positive clinical trial results further validate BCG's therapeutic benefits in bladder cancer, encouraging widespread adoption in medical practice.
North America BCG vaccines market will amass a modest valuation by 2032 due to the rising incidence of Tuberculosis among vulnerable populations and increased awareness of TB prevention. Strong government support and funding for immunization programs ensure widespread vaccine availability and distribution. Additionally, the growing recognition of BCG vaccines' role in treating non-muscle invasive bladder cancer drives their adoption in oncology. Advanced healthcare infrastructure, robust research and development activities, and stringent regulatory standards further support market growth. Public health campaigns and recommendations from health organizations like the CDC reinforce the importance of BCG vaccination, contributing to the market expansion.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Growing incidence of tuberculosis (TB)
- 3.2.1.2 Surge in R&D investments
- 3.2.1.3 Rising awareness and adoption of vaccination programs
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Vaccine shortages and supply chain challenges
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Reimbursement scenario
- 3.5 Regulatory landscape
- 3.6 Technological landscape
- 3.7 Expanding applications of BCG vaccines
- 3.8 Pricing analysis
- 3.9 Porter's analysis
- 3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Pediatrics
- 5.3 Adults
Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Tuberculosis
- 6.3 Bladder cancer
Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Hospitals
- 7.3 Clinics
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 India
- 8.4.2 China
- 8.4.3 Indonesia
- 8.4.4 Philippines
- 8.4.5 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 AJ Biologics Sdn Bhd
- 9.2 BCG Vaccine Laboratory
- 9.3 Biomed Lublin S.A.
- 9.4 GSBPL
- 9.5 Japan BCG Laboratory
- 9.6 Merck & Co., Inc.
- 9.7 Microgen
- 9.8 Serum Institute of India Pvt. Ltd.
- 9.9 Taj Pharmaceuticals Limited
- 9.10 Zydus Group
